Monoclonal antibodies - dawn of a new era

Date: 14 November 2013
Venue: Bird & Bird LLP, Pacellistrasse 14, 80333 Munich

Bird & Bird's renowned regulatory team is delighted to invite you to a seminar focusing on monoclonal antibodies.

MAbs have for a long time been the promise for cancer therapy and other therapeutical applications where traditional pharmaceuticals have not provided the solution. Now they  have emerged as the state of the art therapy for the future. Due to their very nature, they pose different questions and issues than small molecule drugs that are common in the marketplace today.
This seminar will deal with the protection of the investment in MAbs from a regulatory and IP perspective, from the very inception until market launch. It will offer both a practical and a strategic approach for tackling these issues.
If you wish to submit a question ahead of the seminar, for our speakers to answer, please indicate this over email. We will endeavour to answer all questions.

Would you like to attend?

The programme

Coffee and registration


Welcome and introduction
Wouter Pors, Partner, The Netherlands


15.05 - 15.35
MAbs - How to protect them using patents and SPCs
Michael Alt, Partner, Germany


15.35 - 16.05
Infringement issues relating to MAbs
Anna Wolters, Partner, Germany


16.05 - 16.20
Coffee Break


16.20 - 16.50
Comparison of EU & US Biosimilar regulation
Liz Fuller, Consultant, UK


16.50 - 17.20
Legal framework for stem cells and cell therapy in Europe
Marc Martens, Partner, Belgium


17.20 - 17.50
An industry perspective
Frank Landolt, IP and Legal Counsel, Ablynx


17.50 - 18:15
Ask the experts - Q&A with the Panel


Drinks & Canapés